>>> US Notable post-earnings movers

Notable post-earnings movers

  • Post-earnings gainers: DAIO +12.6%, ALGN +10.8%, AMZN +7.9%, GIMO +6.1%, OSIS +5%, ATEN +4.5%, SIVB +4.5%, TRMB +4.3%, BCOV +4.3%, RMD +4.2%, FSLR +4.1%, VDSI +4.1%, MSFT +3.6%, GOOG +3.2%, LOGM +2.4%, EGHT +2.4%, SYK +2.1%, MULE +2.1%
  • Post-earnings losers: SMCI -21.4%, MAT -16.5%, EFII -15.7%, EXPE -14.5%, BIDU -11.6%, FTNT -6.5%, VSAR -6.3%, MERC -2.5%, WDC -2.4%, MHK -2.3%

>>> US Close Dow +0.31% S&P +0.13% Nasdaq -0.11% Russell +0.27%

Closing Market Summary: Trimming Losses

The U.S. equity market claimed a modest victory on Thursday, trimming its loss for the week. Stocks trended sideways for much of the session, but slipped in the final stretch to leave the major indices near the bottom of their narrow trading ranges. The Dow and the S&P 500 added 0.3% and 0.1%, respectively, while the tech-heavy Nasdaq shed 0.1%. The S&P 500 will enter Friday's session with a week-to-date loss of 0.6%.

Investors received another largely positive batch of earnings overnight, with most companies topping expectations. Twitter (TWTR 20.31, +3.17) was one of the most notable post-earnings advancers, rallying 18.5%, after beating earnings estimates and announcing that it could post its first profit ever in the fourth quarter. Similarly, Buffalo Wild Wings (BWLD 120.95, +19.80) soared 19.6% after blowing past profit estimates and raising its earnings guidance for the fiscal year.

Materials showed particular strength on Thursday, sending the S&P 500's materials sector (+1.4%) to the top of the sector standings. Within the group, DowDuPont (DWDP 73.05, +1.96) was among the strongest components, adding 2.8%, after providing upbeat preliminary earnings figures ahead of next week's earnings release.

The heavily-weighted financial sector (+0.6%) also outperformed, helped by the House's vote to pass a budget for fiscal year 2018--the same budget that the Senate passed last week. The budget approval was seen as an important step in the GOP's tax overhaul effort as it allows Republicans to pass a tax reform bill under the reconciliation process, which requires only a simple majority in the Senate vs the typical 60-vote threshold.

While the broader market moved higher on Thursday, the S&P 500's health care sector (-1.0%) struggled from start to finish, keeping the benchmark index's gain in check. Within the group, Celgene (CELG 99.99, -19.57) plunged 16.4% after missing revenue estimates for the third quarter and lowering its 2020 long-term financial targets. The larger biotech industry moved in tandem with Celgene, sending the iShares Nasdaq Biotechnology ETF (IBB 313.98, -7.47) lower by 2.3%.

On a related note, pharmacy names like Walgreens Boot Alliance (WBA 67.11, -2.25) and CVS Health (CVS 73.31, -2.22) dropped 3.2% and 2.9%, respectively, after President Trump declared the nation's opioid crisis a national public health emergency. Reports that Amazon (AMZN 972.43, -0.48) has obtained pharmacy licenses across several states also weighed on retail pharmacy shares.

Also, manged health care giant Aetna (AET 178.60, +18.48) spiked 11.5% in the final minutes of Thursday's session following reports that CVS might be interested in the company.

Elsewhere, the European Central Bank decided to leave interest rates unchanged and announced that it expects to lower its monthly asset purchases to EUR 30 billion from EUR 60 billion in January, as expected. That pace of purchases is expected to continue until at least the end of September 2018.

The euro tumbled 1.4% against the U.S. Dollar to 1.1650 following the ECB's announcement, hitting its lowest level since late July. 

In the bond market, U.S. Treasuries ended Thursday on a lower note, with shorter-dated issues showing relative weakness. The benchmark 10-yr yield climbed one basis point to 2.45%, while the 2-yr yield jumped three basis points to 1.63%. Yields move inversely to prices. 

Reviewing Thursday's economic data, which included weekly Initial Claims, September Pending Home Sales, the Advance report for International Trade in Goods for September, and the Advance report for Wholesale Inventories for September:

  • The latest weekly initial jobless claims count totaled 233,000 while the consensus expected a reading of 235,000. Today's tally was above the revised prior week count of 223,000 (from 222,000). As for continuing claims, they declined to 1.893 million from the revised count of 1.896 million (from 1.888 million).
    • Claims taking procedures continued to be disrupted in Puerto Rico and the Virgin Islands, yet the underlying message in the initial claims data is that it is consistent with a tight labor market.
  • Pending Home Sales were unchanged in September (0.0%). Today's reading follows an revised 2.8% decrease in August (from -2.6%).
  • The Advance report for International Trade in Goods for September showed a deficit of $64.1 billion, up from a deficit of $63.3 billion in August.
  • The Advance report for Wholesale Inventories for September showed an increase of 0.3%. The prior month's reading was revised to +0.8% from +0.9%.

On Friday, investors will receive the advance third quarter GDP report (consensus 2.4%) and the final reading of the University of Michigan Consumer Sentiment Index for October (consensus 101.0). The two reports will cross the wires at 8:30 ET and 10:00 ET, respectively.

  • Nasdaq Composite +21.8% YTD
  • Dow Jones Industrial Average +18.4% YTD
  • S&P 500 +14.4% YTD
  • Russell 2000 +10.3% YTD

Reuters - EXCLUSIVE-Atlantia intends to sweeten Abertis offer in due course-sour

EXCLUSIVE-Atlantia intends to sweeten Abertis offer in due course-sources - Reuters

26-Oct-2017 14:57:38

MILAN/MADRID, Oct 26 (Reuters) - Italy's Atlantia ATL.MI plans to improve its offer for Spain's Abertis ABE.MC to trump a 17.1 billion euros ($20 billion) rival bid from ACS' German subsidiary Hochtief HOTG.DE, two sources close to the matter said on Thursday.

Infrastructure group Atlantia is studying a rejigged cash-and-share bid but wants to wait for Spain's market watchdog to first approve Hochtief's offer before making a move, the sources said.

ACS-Hochtief unveiled their proposal last week but they are still looking for investors who want to team up to acquire Abertis, one of the sources said.

They are also considering selling some Abertis assets, including a minority stake in French motorway group Sanef, should their bid on the Spanish toll-road operator be successful, three sources said.

Atlantia, Hochtief and Sanef all declined to comment on the issues. ($1 = 0.8516 euros)

>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance
:
  • NOK -16.2%, UCTT -11.3%, NTRI -10.8%, TAL -10.8%, CELG -9.8%, MLNX-8.6%, ESND -8%, VAR -6.6%, OII -6.5%, ORLY -6.3%, ONCS -6.1%, JAKK-5.9%, XLNX -5.3%, UHS -5.2%, BCS -5.2%, ALKS -5%, RVLT -5%, POT-4.8%, NOW -4.5%, DLB -4%, SSNC -3.9%, BSX -3.7%, CA -3.5%, MC -3.5%,TSCO -3.3%, HLI -3.2% (also announces secondary offering of class A common stock by selling stockholders), CDE -2.9%, NTGR -2.8%, IART-2.8%, MMLP -2.7%, PKG -2.7%, AMGN -2.6%, DNKN -2.5%, KKR -2.5%,BUD -2.4%, FAF -2.4%, ABMD -2.3%, DB -2.2%, GNC -2.1%, ALLE -1.9%,MDP -1.9%, WPG -1.6%, BMY -1.6%, STO -1.4%, CMO -1%, VC -1%, RJF-0.9%, VRTX -0.9%, ABX -0.9%, PSA -0.8%, ICLR -0.8%
Other news:
  • ATOS -24.5% (proposes public offering of common stock)
  • IDRA -21.7% (prices 33,333,334 shares at $1.50)
  • VBIV -6% (commenced an underwritten public offering and a registered direct offering of its common shares )
  • HCM -4.6% (prices 9,886,792 ADSs at $26.50 per share)
  • CSX -4.5% (light volume; CSX authorized $1.5 billion in share repurchases; is postponing its scheduled October 30th Investor Conference to a later date)
Analyst comments:
  • PCRX -5.8% (downgraded to Sell from Neutral at Janney)
  • PTCT -5.4% (downgraded to Underperform from Neutral at BofA/Merrill)
  • TRVG -1.8% (downgraded to Underperform from Neutral at BofA/Merrill; downgraded to Neutral from Buy at Guggenheim)
  • WWD -1.7% (downgraded to Perform from Outperform at Oppenheimer)
  • GSK -1% (downgraded to Neutral from Buy at BofA/Merrill)
  • LB -1% (downgraded to Neutral from Buy at Buckingham Research)